Amprion is a global leader advancing precision medicine for neurodegenerative disorders through seed amplification testing. Amprion’s SAAmplify™-ɑSYN (formerly SYNTap®) Biomarker Test is a first-in-class, qualitative Laboratory Developed Test (LDT) and the only seed amplification assay available to aid the diagnosis of synucleinopathies (by detecting pathogenic ɑ-synuclein) such as Parkinson’s disease (PD), Lewy body dementia (LBD/DLB), and Alzheimer’s disease (AD) with Lewy body variant.
| Website | https://ampriondx.com |
| Revenue | $14.8 million |
| Employees | 38 (25 on RocketReach) |
| Founded | 2007 |
| Address | 149 New Montgomery St 4fl, San Francisco, California 94105, US |
| Technologies |
JavaScript
,
HTML
,
PHP
+25 more
(view full list)
|
| Industry | Biotechnology, Fitness, Sports, Health Care |
| Keywords | Precision Medicine, Diagnostic Testing, Medical Diagnostics, Neurology, Molecular Diagnostics, Disease Diagnostics, Biomarker Discovery, Clinical Diagnostics, In-Vitro Diagnostics, Drug Development, Genetic Testing, Therapeutics |
| Competitors | Thermo Fisher Scientific, Roche, Abbott, Siemens Healthineers, Bio-Rad Laboratories, PerkinElmer, Inc., Beckman Coulter Diagnostics, Agilent Technologies, GenMark Diagnostics, Hologic, Inc. +35 more (view full list) |
Looking for a particular Amprion employee's phone or email?
The Amprion annual revenue was $14.8 million in 2026.
Richard Narido is the CFO of Amprion.
25 people are employed at Amprion.
Amprion is based in San Francisco, California.